Target intelligence / Profile preview

Toll-like receptor 2–Toll-like receptor 1 heterodimer (TLR2–TLR1 heterodimer)

Target
TLR2–TLR1 heterodimer
Molecular classification
Receptor, Pattern recognition receptor (PRR), Toll-like receptor family, Membrane protein
01

Overview

Toll-like receptor 2–Toll-like receptor 1 heterodimer is a cell-surface pattern recognition receptor complex composed of TLR2 and TLR1 subunits. This heterodimer, primarily located on immune cells such as macrophages and dendritic cells, recognizes specific microbial components, notably triacylated lipopeptides from bacteria, leading to activation of the innate immune response[3][4][6]. Ligand binding induces the formation of an “m”-shaped extracellular domain arrangement, driving close apposition of intracellular TIR (Toll/interleukin-1 receptor) domains and triggering downstream signaling involving the adapter protein MyD88, resulting in production of pro-inflammatory cytokines and type I interferons[4][5][6]. This receptor complex is crucial for early defense against pathogens but is also implicated in inflammatory and autoimmune pathology when dysregulated[3][7][8]. Experimental agonists like Pam3CSK4 and CU-T12-9 specifically activate the TLR2/1 dimer, and its modulation is under investigation for various infectious, inflammatory, and oncological conditions[6][8].

Other names
TLR2/1 heterodimerTLR1/2 complexTLR1–TLR2 receptor complex
02

Mechanism of action

Agonists or ligands induce dimerization, triggering downstream signaling via MyD88 and activation of NF-κB and inflammatory cytokine production; Recognition of triacylated lipopeptides and subsequent immune activation

03

Biological functions

Pathogen recognitionSignal transductionInnate immune response
04

Disease associations

InfectionInflammationCancer (inflammatory tumor microenvironment)Autoimmune disease
05

Safety considerations

Excess activation can promote systemic inflammation and cytokine release (“cytokine storm”)Chronic activation associated with autoimmunity and inflammatory tissue damageTargeting may compromise anti-infective defense or promote tumorigenesis in some contexts
06

Interacting drugs

Pam3CSK4 (synthetic triacylated lipopeptide; tool compound)

2 more in the full profile.

07

Biomarkers

TLR2 and TLR1 expression (as markers of innate immune activation, inflammation)Response to TLR1/2 agonists in functional immune assays

Beyond the preview

Go deeper on Toll-like receptor 2–Toll-like receptor 1 heterodimer (TLR2–TLR1 heterodimer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toll-like receptor 2–Toll-like receptor 1 heterodimer (TLR2–TLR1 heterodimer).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call